|
|||||
|
|
| 生血宁片对非透析慢性肾脏病肾性贫血患者的临床疗效 | |
| 引用本文： | 汤晓静,戎殳,梅长林,倪兆慧,蒋更如,袁伟杰,汪年松,郭志勇,马骏,严海东,张黎明. 生血宁片对非透析慢性肾脏病肾性贫血患者的临床疗效[J]. 中成药, 2019, 0(2): 316-321 |
| 作者姓名： | 汤晓静 戎殳 梅长林 倪兆慧 蒋更如 袁伟杰 汪年松 郭志勇 马骏 严海东 张黎明 |
| 作者单位： | 1.第二军医大学长征医院肾内科;2.上海交通大学附属第一人民医院肾内科;3.上海交通大学医学院附属仁济医院肾内科;4.上海交通大学医学院附属新华医院肾内科 |
| 基金项目： | 上海市卫计委三年行动计划(GWIV-18);上海市重中之重临床重点学科(2017ZZ0209);上海市科委仪器项目(16142203100) |
| 摘 要： | 目的考察生血宁片对非透析慢性肾脏病肾性贫血患者的临床疗效。方法 94例患者随机分为实验组(53例)与对照组(41例),实验组给予生血宁片,对照组给予琥珀酸亚铁片,疗程12周。然后,监测EPO用量、Hb水平、铁代谢指标(SI、SF、TSAT、TIBC)、肝肾功能及不良反应。结果治疗6、8、10、12周后,2组Hb水平显著高于筛选期(P<0. 05),但组间无显著差异(P>0. 05);治疗12周后,2组SI、SF、TSAT显著高于筛选期(P<0. 05),但组间无显著差异(P>0. 05);治疗8、12周后,实验组EPO用量显著低于对照组(P<0. 05)。2组血常规参数无明显变化,并且未发现与研究药物有关的不良反应。结论生血宁片可维持非透析慢性肾脏病肾性贫血患者铁代谢指标,减少EPO用量,安全性良好。 |
| 关 键 词： | 生血宁片 非透析慢性肾脏病 肾性贫血 |
Clinical effects of Shengxuening Tablets on renal anemia patients with non-dialysis chronic kidney disease |
|
| TANG Xiao-jing,RONG Shu,MEI Chang-lin,NI Zhao-hui,JIANG Geng-ru,YUAN Wei-jie,WANG Nian-song,GUO Zhi-yong,MA Jun,YAN Hai-dong,ZHANG Li-ming. Clinical effects of Shengxuening Tablets on renal anemia patients with non-dialysis chronic kidney disease[J]. Chinese Traditional Patent Medicine, 2019, 0(2): 316-321 | |
| Authors: | TANG Xiao-jing RONG Shu MEI Chang-lin NI Zhao-hui JIANG Geng-ru YUAN Wei-jie WANG Nian-song GUO Zhi-yong MA Jun YAN Hai-dong ZHANG Li-ming |
| Affiliation: | (Department of Nephrology,Changzheng Hospital of the Second Military Medical University,Shanghai 200003,China;Department of Nephrology,the First People’s Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200080,China;Department of Nephrology,Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200120,China;Department of Nephrology,Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China;Department of Nephrology,the Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200233,China;Department of Nephrology,Changhai Hospital of the Second Military Medical University,Shanghai 200433,China;Department of Nephrology,Tongji Hospital Affiliated to Tongji University,Shanghai 200065,China;Department of Nephrology,East Hospi-tal Affiliated to Tongji University,Shanghai 200120,China;Department of Nephrology,Shanghai Municipal Zhabei District Central Hospital,Shanghai 200070,China) |
| Abstract: | AIM To investigate the clinical effects of Shengxuening Tablets on renal anemia patients with nondialysis chronic kidney disease.METHODS Ninety-four patients randomly assigned into trial group(n=53)and control group(n=41)went on 12-week treatment course of Shengxuening Tablets(the trial group),or Ferrous Succinate Tablets(the control group).Subsequently,Hb level,iron metabolism indices(SI,SF,TSAT,TIBC),kidney and liver function were detected.EPO comsumption and adverse events were recorded.RESULTS After6-week,8-week,10-week,12-week treatment,significantly higher Hb levels than those in the screening period were demonstrated in the two groups(P<0.05)with no significant inter-group difference(P >0.05).After 12-week treatment,markedly higher SI,SF,TSAT than those in the screening period were observed in the two groups(P<0.05)with no significant inter-group difference(P >0.05).After 8-week,12-week treatment,obviously lower EPO consumption in the trial group than that in the control group was found as well(P<0.05).No obvious changes in routine blood parameters,and no drug-related adverse reactions were observed in the two groups.CONCLUSION With good safety,Shengxuening Tablets maintain iron metabolism and reduce EPO consumption in managing renal anemia patients with non-dialysis chronic kidney disease. |
| Keywords: | Shengxuening Tablets non-dialysis chronic kidney disease renal anemia |
| 本文献已被 CNKI 维普 等数据库收录！ | |